MR-guided SBRT boost for patients with locally advanced or recurrent gynecological cancers ineligible for brachytherapy: feasibility and early clinical experience.
Brachytherapy
Cervical cancer
Gynecological cancer
Mr-guided radiotherapy
Recurrent
SBRT
Stereotactic
Vaginal cancer
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
15 Jan 2022
15 Jan 2022
Historique:
received:
14
12
2021
accepted:
31
12
2021
entrez:
16
1
2022
pubmed:
17
1
2022
medline:
18
3
2022
Statut:
epublish
Résumé
Chemoradiotherapy (CRT) followed by a brachytherapy (BT) boost is the standard of care for patients with locally advanced or recurrent gynecological cancer (LARGC). However, not every patient is suitable for BT. Therefore, we investigated the feasibility of an MR-guided SBRT boost (MRg-SBRT boost) following CRT of the pelvis. Ten patients with LARGC were analyzed retrospectively. The patients were not suitable for BT due to extensive infiltration of the pelvic wall (10%), other adjacent organs (30%), or both (50%), or ineligibility for anesthesia (10%). Online-adaptive treatment planning was performed to control for interfractional anatomical changes. Treatment parameters and toxicity were evaluated to assess the feasibility of MRg-SBRT boost. MRg-SBRT boost was delivered to a median total dose of 21.0 Gy in 4 fractions. The median optimized PTV (PTV These early results report the feasibility of an MRg-SBRT boost approach in patients with LARGC, who were not candidates for BT. When classical BT-OAR constraints are followed, the therapy was well tolerated. Long-term follow-up is needed to validate the results.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Chemoradiotherapy (CRT) followed by a brachytherapy (BT) boost is the standard of care for patients with locally advanced or recurrent gynecological cancer (LARGC). However, not every patient is suitable for BT. Therefore, we investigated the feasibility of an MR-guided SBRT boost (MRg-SBRT boost) following CRT of the pelvis.
MATERIAL AND METHODS
METHODS
Ten patients with LARGC were analyzed retrospectively. The patients were not suitable for BT due to extensive infiltration of the pelvic wall (10%), other adjacent organs (30%), or both (50%), or ineligibility for anesthesia (10%). Online-adaptive treatment planning was performed to control for interfractional anatomical changes. Treatment parameters and toxicity were evaluated to assess the feasibility of MRg-SBRT boost.
RESULTS
RESULTS
MRg-SBRT boost was delivered to a median total dose of 21.0 Gy in 4 fractions. The median optimized PTV (PTV
CONCLUSION
CONCLUSIONS
These early results report the feasibility of an MRg-SBRT boost approach in patients with LARGC, who were not candidates for BT. When classical BT-OAR constraints are followed, the therapy was well tolerated. Long-term follow-up is needed to validate the results.
Identifiants
pubmed: 35033132
doi: 10.1186/s13014-022-01981-z
pii: 10.1186/s13014-022-01981-z
pmc: PMC8760788
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8Informations de copyright
© 2022. The Author(s).
Références
Radiat Oncol. 2019 Jun 3;14(1):92
pubmed: 31167658
Phys Med. 2017 Dec;44:139-149
pubmed: 28242140
Gynecol Oncol. 2011 Mar;120(3):404-12
pubmed: 21194733
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):653-7
pubmed: 21345618
Gynecol Oncol. 1998 Aug;70(2):241-6
pubmed: 9740698
J Med Imaging Radiat Oncol. 2020 Feb;64(1):163-177
pubmed: 31646742
Semin Radiat Oncol. 2014 Jul;24(3):151-9
pubmed: 24931085
Radiother Oncol. 2011 Jul;100(1):116-23
pubmed: 21821305
Radiat Oncol. 2013 May 02;8:109
pubmed: 23638755
Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):118-24
pubmed: 15850911
Radiother Oncol. 2005 Mar;74(3):235-45
pubmed: 15763303
Semin Radiat Oncol. 2014 Jul;24(3):227-32
pubmed: 24931098
Radiother Oncol. 2016 Sep;120(3):412-419
pubmed: 27396811
Front Oncol. 2021 Aug 27;11:628131
pubmed: 34513656
Radiother Oncol. 2008 Nov;89(2):197-204
pubmed: 18237803
Jpn J Clin Oncol. 2019 Sep 1;49(9):856-861
pubmed: 31112278
Clin Transl Radiat Oncol. 2018 Jan 11;9:48-60
pubmed: 29594251
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):129-35
pubmed: 22503523
Strahlenther Onkol. 2003 Nov;179(11):742-7
pubmed: 14605743
Front Oncol. 2012 Mar 21;2:25
pubmed: 22655266
Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):464-471
pubmed: 31697990
Radiother Oncol. 2012 Jun;103(3):305-13
pubmed: 22633469
Radiother Oncol. 2016 Sep;120(3):441-446
pubmed: 27350396
Radiother Oncol. 2010 Jan;94(1):53-9
pubmed: 20079550
Radiother Oncol. 2008 Aug;88(2):233-40
pubmed: 18237798
Biomed Res Int. 2013;2013:898953
pubmed: 24000329
Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):772-8
pubmed: 18207658
Cancers (Basel). 2021 Mar 26;13(7):
pubmed: 33810244